Paper Chase #5 | Management of Obesity Outcomes With or Without Gastric BypassFrom May 2018, The Buzz That Won't Quit
In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point (A1c < 7%, LDL < 100 mg/dL, systolic blood pressure < 130) in the surgical …4min 22Andrew Buelt, DO and Joe Weatherly, DO
Lifestyle and Diabetes - Part 2From April 2018, Will You Be My Facebook Friend?
In part 2 of this segment on lifestyle and diabetes,Neil and Heidi review yet more evidence pointing toward the effectiveness of weight management and exercise in preventing and managing DM2. As a bonus, Neil concludes his story of how exercise has changed his life and health.17min 43Heidi James, MD and Neil Skolnik, MD
Paper Chase #3 - ACE Inhibitors and Statins in Adolescents with Type 1 DiabetesFrom March 2018, What’s Your (Code) Status?
ACE inhibitors and statins did not change the albumin to creatinine ratio over time in this study population.2min 54Andrew Buelt, DO and Joe Weatherly, DO
PrediabetesFrom March 2018, What’s Your (Code) Status?
There is plenty of rock solid evidence showing the role of exercise and weight loss in preventing DM 2. In fact, in the Diabetes Prevention Program Outcomes Study, participants who were asked to lose 7% of their body weight and exercise 150 minutes/week decreased their risk of developing DM2 by …16min 51Neil Skolnik, MD and Heidi James, MD
Paper Chase #1 - The CANVAS TrialFrom November 2017, Lytes and Bites
SGLT-2 inhibitor canagliflozin is associated with lower cardiovascular events but greater amputation rates than placebo.6min 44Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 2 - SWITCH 1 TrialFrom September 2017, You Can Do It!!
The SWITCH 1 trial compared rates of hypoglycemia in patients with Type 1 DM taking either insulin degludec and or insulin glargine U100. While degludec treatment was associated with fewer instances of hypoglycemia than glargine, as it was also the case in patients with DM 2, Joe and Andrew do not …2min 50Andrew Buelt, DO and Joe Weatherly, DO
Paperchase 1 - The SWITCH 2 TrialFrom September 2017, You Can Do It!!
The SWITCH 2 trial compared rates of hypoglycemia in patients with Type 2 DM taking either insulin degludec and or insulin glargine U100. While degludec treatment was associated with fewer instances of hypoglycemia, Joe and Andrew do not feel it is clinically significant. •8min 3Andrew Buelt, DO and Joe Weatherly, DO
Diabetes Meds 101From August 2017, Diabetes and Whispered Pectorilo….what???
There are no shortage of medications to choose from in the management of Type 2 diabetes! We review the pharmacologic classes with attention to their unique features and drawbacks. •24min 10Neil Skolnik, MD, Heidi James, MD, and Mizuho Morrison, DO
Antipsychotic Side EffectsFrom April 2017, Antibiotics in the Lyme-Light
Antipsychotics are frequently used to treat mental health conditions. They are associated with several common side effects that primary care physicians needs to be family with. These include, metabolic syndrome, hyperprolactinemia, akathisia, acute dystonia, neuroleptic malignant syndrome …11min 31Shawn Hersevoort, MD, MPH and Rob Orman, MD
The Primary Care RAP Hot Sheet: March 2017From March 2017, The Primary Care RAP Hot Sheet: March 2017
This month, Andrew and Joe suffer from some entertaining loosening of associations as they connect obscure March holidays to recent studies on flexible sigmoidoscopy, lung cancer screening, and metformin in chronic kidney disease. (Spoiler: Awkward Moment Day is an actual thing.) •5min 36Andrew Buelt, DO, Joe Weatherly, DO, and Heidi James, MD
Paper Chase 2: Blood Glucose Test Strip Quantity-Limit PoliciesFrom March 2017, The Benzos & Fungus Among Us
Quantity limits for blood glucose test strips was not associated with worsening short-term outcomes, suggesting that these policies can reduce costs associated with test strips without causing patient harm. •4min 37Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 1: Prediabetes with All-Cause and Cardiovascular MortalityFrom March 2017, The Benzos & Fungus Among Us
A diagnosis of pre-diabetes was weakly associated with increased risk of cardiovascular disease and all cause mortality. There are some flaws in the study that call these results into question. •6min 1Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 2: Semaglutide and Cardio Outcomes in Patients with Type 2 DiabetesFrom February 2017, Sweat Puddled, Brains Muddled
Semaglutide was found to be non-inferior to placebo in the secondary prevention of fatal and nonfatal MI or stroke in composite primary endpoints.4min 51Andrew Buelt, DO and Joe Weatherly, DO
The Primary Care RAP Hot Sheet: December 2016From December 2016, The Primary Care RAP Hot Sheet: December 2016
Andrew and Heidi talk about medical marijuana legislation, new statin guidelines, and the diabetes drug that has everyone talking.5min 55Andrew Buelt, DO and Heidi James, MD
The Primary Care RAP Hot Sheet: November 2016From November 2016, The Primary Care RAP Hot Sheet: November 2016
This month, Andrew and Heidi scoured the web for all things fitness and diabetes related and found.6min 44Andrew Buelt, DO and Heidi James, MD
Paper Chase 3: BP Targets in DiabetesFrom November 2016, Aspirin Loses Its Tenure
Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg. If systolic blood pressure is less than 140 mm Hg, however, further treatment is associated with an increased risk of …6min 1Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 3: DPP-4 Inhibitors and Heart Failure Risk for Type 2 DiabetesFrom August 2016, Feeling Restless
This study found no statistically significant change in heart failure in type 2 diabetes patients on DPP4 therapy. •3min 38Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 5: Treatment of Painful Diabetic NeuropathyFrom July 2016, Creme de la Thyroid
Several medications may be effective for short-term management of painful diabetic neuropathy, although their comparative effectiveness is unclear. •5min 5Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 1: Empagliflozin and Mortality in Type 2 Diabetic PatientsFrom January 2016, Palliative Cerumen Emergencies
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. •7min 15Andrew Buelt, DO and Joe Weatherly, DO
Prediabetes?From September 2015, Consider the Prostate
“Prediabetes” is often called a risk factor for a risk factor. Whatever your opinion of the term, finding a borderline A1c elevation can spark conversation about improving lifestyle. •22min 31Mike Mooney, MD and Kevin Wineinger, MD
‹ PreviousNext ›